StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a research note published on Monday morning. The firm issued a sell rating on the stock.

A number of other analysts have also recently commented on CTLT. Barclays increased their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a research note on Friday, June 28th. Royal Bank of Canada reiterated a sector perform rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of Hold and an average target price of $58.08.

Catalent Trading Down 0.6 %

NYSE:CTLT opened at $60.35 on Monday. The company’s 50-day simple moving average is $58.80 and its 200 day simple moving average is $57.06. The firm has a market capitalization of $10.92 billion, a P/E ratio of -9.89, a PEG ratio of 2.52 and a beta of 1.16. Catalent has a one year low of $31.80 and a one year high of $61.20. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77.

Insiders Place Their Bets

In other news, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares in the company, valued at $10,431,133.96. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Alessandro Maselli sold 9,088 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the transaction, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ricky Hopson sold 662 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The disclosure for this sale can be found here. Insiders have sold 13,409 shares of company stock worth $782,923 in the last quarter. 0.31% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Catalent

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lindbrook Capital LLC lifted its stake in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares during the period. GAMMA Investing LLC bought a new position in shares of Catalent in the 4th quarter worth $33,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Catalent during the second quarter valued at about $42,000. Mather Group LLC. bought a new stake in Catalent in the 1st quarter worth approximately $52,000. Finally, Longfellow Investment Management Co. LLC grew its holdings in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.